Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 December 2017Next earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
DNLI Latest News
Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
Denali Therapeutics Inc. is currently investigating DNL-310 in a phase 2/3 COMPASS study for patients with MPS II, with enrollment completion anticipated in 2024. The company is in discussions with the FDA's CDER division to pursue the Accelerated Approval pathway for DNL-310 in MPS II. Data on biomarkers and safety from a phase 1/2 study using DNL-126 for MPS IIIA patients is expected by the end of 2024.
Denali Therapeutics (DNLI) has experienced positive changes in earnings estimates in the last month and is part of a robust industry.
Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly.
While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by major indices such as the S&P 500 and the Dow Jones Industrial Average (DJIA) which have been running close to record highs with generally favorable forecasts.
- 1(current)
What type of business is Denali Therapeutics?
Denali Therapeutics Inc. specializes in developing methods for treating patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and others. Denali Therapeutics was registered in 2013, with its headquarters located in South San Francisco, California. In the Company's diversified portfolio, drug development is based on scientific understanding of the genetic causes and biological processes underlying neurodegenerative diseases. The company is conducting research programs on the Lysosomal Function Pathway, Glial Nature Pathway, and Cellular Homeostasis Pathway. Its candidate drugs include DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
What sector is Denali Therapeutics in?
Denali Therapeutics is in the Healthcare sector
What industry is Denali Therapeutics in?
Denali Therapeutics is in the Biotechnology industry
What country is Denali Therapeutics from?
Denali Therapeutics is headquartered in United States
When did Denali Therapeutics go public?
Denali Therapeutics initial public offering (IPO) was on 08 December 2017
What is Denali Therapeutics website?
https://www.denalitherapeutics.com
Is Denali Therapeutics in the S&P 500?
No, Denali Therapeutics is not included in the S&P 500 index
Is Denali Therapeutics in the NASDAQ 100?
No, Denali Therapeutics is not included in the NASDAQ 100 index
Is Denali Therapeutics in the Dow Jones?
No, Denali Therapeutics is not included in the Dow Jones index
When was Denali Therapeutics the previous earnings report?
No data
When does Denali Therapeutics earnings report?
The next expected earnings date for Denali Therapeutics is 07 November 2024